Американское общество гирудотерапии

Trigger Finger (Stenosing Tenosynovitis)

Investigational use for stenosing tenosynovitis of the digital flexor pulleys; small case series.

Tier C — InvestigationalИсследовательское применениеLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Краткая информация для пациента

Есть ли FDA-допуск для этого показания?
Not FDA-cleared for trigger finger. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is investigational.
Какие доказательства существуют?
Tier C (investigational). One small case series describes symptomatic improvement; there are no randomized controlled trials. Evidence-based first-line therapy is observation with activity modification and splinting for mild cases, intra-tendon-sheath corticosteroid injection (highest non-surgical evidence; about 60 percent successful at 1 year), and percutaneous or open A1-pulley release for refractory cases. Hand-surgery outcomes are excellent and durable.
Основные риски
  • Bleeding from bite sites for 6 to 24 hours after detachment
  • Bruising and tenderness over the palm for 5 to 10 days
  • Local skin infection or, rarely, Aeromonas infection
  • Allergic reaction to leech saliva (uncommon)
  • Temporary worsening of finger triggering or pain for 1 to 3 days
  • Damage to the digital neurovascular bundle if placement is improperly midline
  • Small permanent scars at bite sites on a visible hand surface
  • Delay or replacement of an effective corticosteroid injection or A1-pulley release
Кому не следует это рассматривать
  • Patients with locked finger requiring urgent release
  • Patients within 4 weeks of a local corticosteroid injection
  • Patients with active palm infection or paronychia
  • Patients with diabetes-related tenosynovitis affecting multiple digits (consider systemic management)
  • Patients on anticoagulants, with hemophilia, or with severe anemia
  • Patients who have not tried evidence-based corticosteroid injection
О чём спросить врача
  • Has my trigger finger been confirmed (A1 pulley stenosing tenosynovitis)?
  • Have I tried splinting and at least one intra-tendon-sheath corticosteroid injection?
  • If injection fails, am I a candidate for percutaneous or open A1-pulley release?
  • Do I have diabetes (which worsens response to injection)?
  • What evidence supports leech therapy specifically for trigger finger?
  • Where exactly will leeches be placed — clearly off the digital neurovascular bundle?
  • What is the practitioner's experience and Aeromonas-prevention plan?
Когда срочно обратиться за медицинской помощью
  • A finger locked in flexion that you cannot release
  • Sudden severe finger pain, swelling, or inability to move
  • Spreading redness, warmth, pus, or red streaks on the hand (cellulitis or flexor tenosynovitis is a surgical emergency)
  • Bleeding from a bite site lasting more than 24 to 48 hours
  • Fever above 38.0 C / 100.4 F or chills
  • Numbness or coldness in the finger
  • Hives, throat tightness, or breathing difficulty

Что это НЕ означает

  • This is not FDA-cleared for trigger finger.
  • A single small case series does NOT establish efficacy versus corticosteroid injection or A1-pulley release.
  • Mechanism rationale (anti-inflammation at A1 pulley) does NOT establish clinical efficacy.
  • Leech therapy is not a substitute for a well-placed corticosteroid injection or hand-surgical release.
  • A locked digit needing release should NOT be deferred for complementary therapy.

Перекрёстные ссылки безопасности

Clinical Profile

Category
musculoskeletal
ICD-10
M65.30, M65.311, M65.312, M65.321, M65.322
Safety tier
low

Evidence Summary

No controlled clinical trial or credible case series of leech therapy for trigger finger (stenosing tenosynovitis) has been published; there is no reliable evidence that it resolves triggering. Any proposed mechanism (anti-inflammatory salivary peptides reducing flexor tenosynovial swelling at the A1 pulley) is speculative and unproven. Conventional management — corticosteroid injection, and percutaneous or open A1 pulley release for refractory cases — remains the standard. ASH position: any use of leech therapy for trigger finger is investigational and mechanistic only.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

  1. Kumar A et al. (2019), n=18

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • Active local infection
  • Recent (<4 weeks) local corticosteroid injection

Related Conditions

Этот сайт предоставляет образовательную информацию и не является медицинской консультацией, диагнозом или рекомендацией по лечению. Гирудотерапия сопряжена с клинически значимыми рисками и должна проводиться только квалифицированными клиницистами в рамках институционально утверждённых протоколов. Разрешение FDA 510(k) для медицинских пиявок ограничено определёнными показаниями; обсуждения исследовательского и нелицензионного применения отмечены соответствующим образом. Для индивидуальных медицинских рекомендаций обратитесь к квалифицированному медицинскому специалисту.

Trigger Finger (Stenosing Tenosynovitis) — Hirudotherapy Evidence | ASH